Proteome sells exclusive license to DiagnostIQ test to Bayer CropScience

With the lifting of two moratoria on genetically modified crops in Australia recently, so did the inevitably polarised debate take off. Those for and against are unlikely to change their minds and, unfortunately, some scientists are now afraid to speak theirs.

Point-of-care testing is an emerging field within community medicine and will be discussed at this week's South Pacific Congress in Auckland.

"World's first" diagnostics company up and running.

A new drug has been shown to improve blood flow in diseased arteries, reducing the risk of high blood pressure and heart attacks, a Monash University study has revealed.

Western Australia's agriculture minister, Kim Chance, is taking what many are now seeing as an overly cautious stance on biotechnology. Graeme O'Neill reports.

The taskforce appointed by the Australian Oilseeds Federation and the Australian Seeds Federation to investigate the recent detection of genetically modified canola seed in a small, non-GM shipment has found the contamination was limited to just one commercial cultivar.

The Brain Resource Company (ASX:BRC) has been granted approval from the US FDA to market its methodology and standardised international human brain database.

Could 'farmer power' force Australian state governments to back down on their moratoria on GM crops? Graeme O'Neill reports.

Routine tests by the Australian Barley Board have detected traces of genetically modified canola seed in a small consignment canola to Japan, triggering a strong reaction from anti-GM activist organisations.

EU environment ministers dealt a blow to efforts to get more GMO crops grown in Europe as they agreed to uphold eight national bans on genetically modified maize and rapeseed types.